Neoadjuvant Chemoimmunotherapy in Stage III NSCLC: New Hope for “Unresectable” Disease? скачать в хорошем качестве

Neoadjuvant Chemoimmunotherapy in Stage III NSCLC: New Hope for “Unresectable” Disease?

🚨 The OncoAlert x VJOncology Journal Club 🚨 This week, we’re joined by Dr. Biagio Ricciuti, Thoracic Oncologist at Dana-Farber Cancer Institute, for an in-depth look at a major new study redefining the boundaries of surgery in stage III non-small cell lung cancer (NSCLC). 📚 Study discussed: A multi-center retrospective analysis evaluating neoadjuvant chemoimmunotherapy in patients with borderline resectable or unresectable stage III NSCLC (T4/N2 multistation or N3 disease). 💡 Key takeaways: ✅ 75% underwent successful resection (96% R0 rate) ✅ 29% pathologic complete response (pCR) ✅ High pCR in smokers & PD-L1-high tumors ❌ No pCR in patients with KRAS-STK11 or KRAS-KEAP1 mutations 👉 Could this strategy shift the standard of care for high-risk stage III NSCLC? 👉 How should biomarkers guide patient selection for neoadjuvant chemo-IO? Join us as Dr. Ricciuti breaks it all down and discusses the implications for clinical practice and future trials. 📺 Like, Subscribe & Hit the 🔔 to stay current with OncoAlert x VJOncology Journal Club – your weekly deep dive into the latest in cancer research! #NSCLC #LungCancer #OncoAlert #VJOncology #Chemoimmunotherapy #JournalClub #ThoracicOncology #Immunotherapy #DanaFarber #CancerResearch #MedicalOncology #Neoadjuvant #PDL1 #KRAS #STK11